Junichi Yoshii
Overview
Explore the profile of Junichi Yoshii including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
757
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kaji K, Yoshiji H, Ikenaka Y, Noguchi R, Aihara Y, Douhara A, et al.
J Gastroenterol
. 2013 Mar;
49(3):481-91.
PMID: 23475323
Background: Dipeptidyl peptidase-4 inhibitor (DPP4-I) is clinically used as a new oral antidiabetic agent. Although DPP4 is reportedly associated with the progression of chronic liver diseases, the effect of DPP4-I...
2.
Kitade M, Yoshiji H, Kojima H, Ikenaka Y, Noguchi R, Kaji K, et al.
Mol Med Rep
. 2011 Apr;
1(4):543-8.
PMID: 21479447
Reactive oxygen species (ROS) is known to play an important role in the pathogenesis of non-alcoholic steatohepatitis (NASH); however, as we previously reported, angiogenesis also plays a pivotal role in...
3.
Yoshiji H, Noguchi R, Ikenaka Y, Kaji K, Aihara Y, Shirai Y, et al.
Int J Mol Med
. 2011 Apr;
28(1):81-8.
PMID: 21455560
An effective therapeutic strategy for suppressing liver fibrosis development should improve the overall prognosis of patients with chronic liver diseases. Despite efforts to develop anti-fibrotic agents, no drugs have yet...
4.
Kaji K, Yoshiji H, Kitade M, Ikenaka Y, Noguchi R, Shirai Y, et al.
Am J Physiol Gastrointest Liver Physiol
. 2011 Mar;
300(6):G1094-104.
PMID: 21372165
Angiotensin II type I receptor blocker and iron chelator reportedly exert suppressive effects on nonalcoholic steatohepatitis (NASH) progression, including liver fibrosis and hepatocarcinogenesis. The aim of this study was to...
5.
Namisaki T, Yoshiji H, Noguchi R, Ikenaka Y, Kitade M, Kaji K, et al.
J Angiogenes Res
. 2010 Aug;
2:16.
PMID: 20731881
Although administration of the vascular endothelial growth factor (VEGF), a potent angiogenic factor, could improve the overall survival of destroyed sinusoidal endothelial cells (SEC) in chemically induced murine acute hepatic...
6.
Noguchi R, Yoshiji H, Ikenaka Y, Kaji K, Shirai Y, Aihara Y, et al.
Int J Mol Med
. 2010 Jul;
26(3):407-13.
PMID: 20664958
Although non-alcoholic steatohepatitis (NASH) may progress to cirrhosis and hepatocellular carcinoma (HCC), no effective therapeutic modalities have been fully established yet. Recent studies have shown that the renin-angiotensin-aldosterone-system plays an...
7.
Kaji K, Yoshiji H, Kitade M, Ikenaka Y, Noguchi R, Shirai Y, et al.
Hepatol Res
. 2010 Apr;
40(5):540-9.
PMID: 20412330
Aim: The renin-angiotensin-aldosterone system (RAAS) has become known as a prerequisite for tumor angiogenesis, including hepatocellular carcinoma (HCC). Although angiotensin II is known to play an important role in tumor...
8.
Noguchi R, Yoshiji H, Ikenaka Y, Namisaki T, Kitade M, Kaji K, et al.
Oncol Rep
. 2009 Jul;
22(2):355-60.
PMID: 19578777
Pancreatic cancer is one of the leading causes of cancer death, and represents a challenging chemotherapeutic problem. The crucial role of angiogenesis in tumor growth has been widely recognized, and...
9.
Yoshiji H, Noguchi R, Ikenaka Y, Namisaki T, Kitade M, Kaji K, et al.
BMC Res Notes
. 2009 May;
2:70.
PMID: 19416517
Background: Apart from simple steatosis, the non-alcoholic steatohepatitis (NASH) can progress into liver fibrosis and cirrhosis. To date, however, no widely accepted therapeutic modalities have been established against NASH in...
10.
Yoshiji H, Noguchi R, Kitade M, Kaji K, Ikenaka Y, Namisaki T, et al.
J Gastroenterol
. 2009 Mar;
44(5):483-91.
PMID: 19319465
Background: Branched-chain amino acids (BCAAs) reportedly inhibit the incidence of hepatocellular carcinoma (HCC) in patients with liver cirrhosis and obesity that is frequently associated with insulin resistance (IR). However, the...